News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
692,529 Results
Type
Article (39380)
Company Profile (247)
Press Release (652902)
Section
Business (204026)
Career Advice (2005)
Deals (35404)
Drug Delivery (93)
Drug Development (80940)
Employer Resources (169)
FDA (16133)
Job Trends (14828)
News (344874)
Policy (32473)
Tag
Academia (2535)
Alliances (49313)
Alzheimer's disease (1314)
Approvals (16117)
Artificial intelligence (199)
Bankruptcy (357)
Best Places to Work (11637)
Biotechnology (175)
Breast cancer (225)
Cancer (1710)
Cardiovascular disease (128)
Career advice (1669)
CAR-T (121)
Cell therapy (353)
Clinical research (65243)
Collaboration (659)
Compensation (370)
COVID-19 (2563)
C-suite (160)
Data (1629)
Diabetes (211)
Diagnostics (6282)
Earnings (85436)
Employer resources (146)
Events (110862)
Executive appointments (564)
FDA (17034)
Funding (602)
Gene therapy (245)
GLP-1 (648)
Government (4357)
Healthcare (18767)
Infectious disease (2674)
Interviews (310)
IPO (16460)
Job creations (3627)
Job search strategy (1420)
Layoffs (437)
Legal (7885)
Lung cancer (255)
Manufacturing (235)
Medical device (13261)
Medtech (13266)
Mergers & acquisitions (19319)
Metabolic disorders (548)
Neuroscience (1715)
NextGen: Class of 2025 (6509)
Non-profit (4475)
Northern California (2090)
Obesity (306)
Opinion (193)
Patents (162)
People (56828)
Phase I (20315)
Phase II (28744)
Phase III (21397)
Pipeline (711)
Postmarket research (2562)
Preclinical (8575)
Radiopharmaceuticals (241)
Rare diseases (321)
Real estate (5897)
Regulatory (21917)
Research institute (2311)
Resumes & cover letters (349)
Southern California (1791)
Startups (3567)
United States (18436)
Vaccines (611)
Weight loss (208)
Date
Today (11)
Last 7 days (593)
Last 30 days (2480)
Last 365 days (34385)
2025 (4427)
2024 (35217)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29264)
2010 (27328)
Location
Africa (716)
Arizona (211)
Asia (37506)
Australia (6133)
California (4761)
Canada (1715)
China (392)
Colorado (217)
Connecticut (230)
Europe (80384)
Florida (688)
Georgia (165)
Illinois (455)
Indiana (259)
Japan (121)
Maryland (739)
Massachusetts (3602)
Michigan (198)
Minnesota (334)
New Jersey (1347)
New York (1359)
North Carolina (833)
Northern California (2090)
Ohio (173)
Pennsylvania (1098)
South America (1093)
Southern California (1791)
Texas (701)
Utah (143)
Washington State (467)
692,529 Results for "vaxxas inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Vaxxas Completes Enrollment for Largest Clinical Trial of High-Density Microarray Patch (HD-MAP) For Vaccine Delivery
February 18, 2025
·
6 min read
Press Releases
Vaxxas Appoints Leading Global Vaccine Experts as the Company Advances its Needle-Free Vaccination Technology Towards Late-Stage Clinical Trials
February 6, 2025
·
6 min read
Press Releases
Vaxxas and CEPI Advance US$4.8 million (AU$7.2 million) Program for Needle-Free Thermostable mRNA Vaccines
January 23, 2025
·
8 min read
Press Releases
Vaxxas Expands Global Intellectual Property Portfolio for Exclusive Manufacture and Sale of Needle-Free Vaccination Technology
November 25, 2024
·
5 min read
Press Releases
Vaxxas Licenses Next-Generation Vaccine for Respiratory Syncytial Virus (RSV) from the United States National Institutes of Health (NIH)
October 28, 2024
·
6 min read
Press Releases
Vaxxas Initiates Phase I Clinical Trial of Pre-Pandemic Avian Influenza A Virus (H7N9) Vaccine Delivered Using Vaxxas’ Novel High-Density Microarray Patch (HD-MAP)
September 11, 2024
·
6 min read
Genetown
Vaccine Journal Highlights the Potential for Self-Administration of Vaccines Using Vaxxas High-Density Microarray Patch (HD-MAP)
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced a publication in the journal Vaccine entitled “Vaccine microarray patch self-administration: An innovative approach to improve pandemic and routine vaccination rates.”
October 18, 2023
·
6 min read
Business
Vaxxas Appoints Rochelle Chaiken, M.D., as Chief Medical Officer
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform technology, announced the appointment of Rochelle Chaiken, M.D., as Chief Medical Officer.
June 5, 2023
·
4 min read
SK bioscience and Vaxxas Enter Joint Development Agreement for Needle-Free Patch Delivery of Typhoid Vaccine
SK bioscience announced that the company has entered into a collaboration agreement with Vaxxas, an Australian biotechnology company developing a unique vaccine patch platform technology, to develop a second-generation typhoid conjugate vaccine with support from Wellcome.
August 23, 2023
·
8 min read
Biotech Bay
Vaxxas Awarded US$3.67 million (AU$5.4 million) from global charitable foundation, Wellcome, for Human Clinical Study of Typhoid Vaccination using Needle-Free Vaccine Patch
Vaxxas announced that the global charitable foundation, Wellcome, has made an award totaling US$3.67 million to conduct IND-enabling studies and a first-in-human clinical study for a potentially second generation typhoid vaccine delivered by Vaxxas’ proprietary high-density microarray patch platform technology.
August 23, 2023
·
8 min read
1 of 69,253
Next
